US-based medical device company Essential Medical has secured investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) to initiate the clinical trial of its large bore vascular closure device, Manta.

Manta is a vascular closure device, based on anchor / plug sealing technologies, which uses common absorbable biomaterials and is equipped with x-ray visibility and improved deployment control.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The pivotal trial is intended to assess the safety and efficacy of Manta as it is deployed at femoral arterial access sites in patients undergoing percutaneous procedures using sheaths ranging from 10F to 24F.

"Safe, reproducible percutaneous large bore closure is needed before transfemoral TAVR can become the default strategy in most patients."

Manta is expected to provide a safe, percutaneous closure in a variety of large bore procedures.

It is applicable on a range of procedures namely transfemoral transcatheter aortic valve replacement (TAVR), endovascular aortic repair (EVAR) of abdominal aortic aneurysms (AAA), ventricular assist devices (VAD), and balloon aortic valvuloplasty (BAV).

See Also:

Centre for Heart Valve Innovation in Vancouver Canada founding member and US Manta trial co-principal investigator Dr David Wood said: "While transfemoral TAVR has advanced rapidly and can now be safely performed in fully awake patients in less than 30 minutes, the vascular closure method for these cases has not progressed and access site related complications remain a concern.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Safe, reproducible percutaneous large bore closure is needed before transfemoral TAVR can become the default strategy in most patients."

Manta is intended to address the complexities associated with large bone procedures like morbidity, longer procedure time and cost.

The company noted that its simple and fail-safe deployment results to an immediate hemostasis which will reduce the complications and cost associated with large bore closure.